Meteora (MET) fluctuates 63.7% in 24 hours: Trading volume surge and technological breakthrough drive rebound
Bitget Pulse2026/04/22 16:02Summary of Volatility
In the past 24 hours, MET price rebounded from a low of $0.1489 to a high of $0.2438, currently quoted at $0.1854, with a volatility of 63.7% and a 24-hour increase of approximately 26-29%. Trading volume surged to $250-270 million, up over 3000% from the previous day, and the market capitalization is around $97 million.
Brief Analysis of Abnormal Movements
- Trading volume surge and technical breakthrough: The price broke through a key resistance level, accompanied by a sharp increase in trading volume from a low point, fueling the rebound.
- Solana ecosystem support: Meteora TVL exceeds $415 million, fee generation is active, but there were no official announcements or whale transactions within the past 24 hours.
Market Perspectives and Outlook
Community sentiment is bullish, with discussions on X platform focusing on the price pump and dominance of long positions. Analysts predict that if the breakout is sustained, MET could rise over 30% further; however, tomorrow (April 23), 7.33M MET (worth about $1.4 million) will be unlocked, which may increase selling pressure, raising the risk of a pullback.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
AMD (AMD.US) Surpasses $1 Trillion Market Cap and Begins Competing for "Computing Power Definition Rights"! Officially Announces $8.2 Billion Acquisition of Fei-Fei Li's World Labs
AMD has agreed to acquire World Labs for $8.2 billion, thereby gaining access to the artificial intelligence startup founded by industry pioneer and researcher Fei-Fei Li. This acquisition is expected to help AMD plan its future hardware launches by bringing in a team of top researchers and their models, as well as deep insights into trends in the field of artificial intelligence.
Crypto prices
More
